ZYME — Zymeworks Inc.
$28.22-0.77%
Last close: · regular session
Last 60 sessions
ZYME closed at $28.22 (-0.77%) on Oct 23, 2026. Float: 73.9M shares. Latest SEC filing: 8-K on Sep 23, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ZYME in the TickerWise workspace.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ
- Employees: 299
- Website: https://www.zymeworks.com
Latest SEC filings for ZYME
Latest ZYME news
- Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer Read article
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 Read article
- Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 Read article
- Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results Read article
- Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook Read article
- Zymeworks Inc. (ZYME) M&A Call Transcript Read article
- Zymeworks outlines guidance following Theravance acquisition Read article
- Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.